After treatment , the ovarian mass volumes measured with type-B ultrasound , the scores of the patient 's subjective symptoms during non-menstrual and menstruation days , the pelvic signs during non-menstrual days , the changes of hormones [ estradiol ( E2 ) , FSH , LH ] , and adverse events were observed .